

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11578013/publications.pdf>

Version: 2024-02-01

88
papers

9,321
citations

87843

38
h-index

53190

85
g-index

91
all docs

91
docs citations

91
times ranked

14500
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). <i>Trials</i> , 2022, 23, 307.	0.7	2
2	The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. <i>Lancet Psychiatry</i> , 2022, 9, 477-486.	3.7	13
3	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-174.	1.3	16
4	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 735-750.	2.7	83
5	Count the cost of disability caused by COVID-19. <i>Nature</i> , 2021, 593, 502-505.	13.7	64
6	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. <i>Pharmacoeconomics</i> , 2021, 39, 1201-1208.	1.7	8
7	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. <i>Clinical Colorectal Cancer</i> , 2021, 20, 236-244.	1.0	2
8	Artificial neural network metamodel for sensitivity analysis in a total hip replacement health economic model. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 629-640.	0.7	7
9	A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. <i>Journal of Medical Economics</i> , 2020, 23, 64-69.	1.0	4
10	Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. <i>European Journal of Health Economics</i> , 2020, 21, 1197-1209.	1.4	4
11	Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. <i>BMJ Open</i> , 2020, 10, e034209.	0.8	3
12	Type 2 diabetes remission: 2-year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DIRECT)/Counterweight-Plus weight management programme. <i>Diabetologia</i> , 2020, 63, 2112-2122.	2.9	26
13	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020, 80, 5427-5434.	0.4	77
14	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , 2020, 40, 460-473.	1.2	15
15	Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials. <i>Pharmacoeconomics - Open</i> , 2020, 4, 649-655.	0.9	1
16	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. <i>JMIR Research Protocols</i> , 2020, 9, e15058.	0.5	24
17	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1096-1104.	2.3	33
18	Enhancing Health Through Access to Nature: How Effective are Interventions in Woodlands in Deprived Urban Communities? A Quasi-experimental Study in Scotland, UK. <i>Sustainability</i> , 2019, 11, 3317.	1.6	20

#	ARTICLE	IF	CITATIONS
19	Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. <i>Oncology and Therapy</i> , 2019, 7, 141-157.	1.0	3
20	Cardiac Troponin T and Troponin I in the General Population. <i>Circulation</i> , 2019, 139, 2754-2764.	1.6	200
21	Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice Experiment. <i>MDM Policy and Practice</i> , 2019, 4, 238146831983792.	0.5	5
22	Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 169-172.	5.5	22
23	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 2019, 4, 108.	0.9	9
24	Health impacts of environmental and social interventions designed to increase deprived communities' access to urban woodlands: a mixed-methods study. <i>Public Health Research</i> , 2019, 7, 1-172.	0.5	19
25	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , 2018, 19, 562-578.	5.1	133
26	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1548.	3.8	67
27	Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. <i>Pharmacoeconomics</i> , 2018, 36, 1421-1426.	1.7	63
28	Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. <i>Clinical Chemistry</i> , 2018, 64, 1607-1616.	1.5	101
29	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. <i>BMJ Open</i> , 2017, 7, e014849.	0.8	1
30	Comparison of behavioural activation with guided self-help for treatment of depression in adults with intellectual disabilities: a randomised controlled trial. <i>Lancet Psychiatry</i> , 2017, 4, 909-919.	3.7	52
31	A View from the Bridge: Health Economic Evaluation – A Value-Based Framework?. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1499-1502.	0.8	10
32	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. <i>Value in Health</i> , 2016, 19, 921-928.	0.1	203
33	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2016, 19, 704-719.	0.1	101
34	Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. <i>Social Science and Medicine</i> , 2016, 169, 141-148.	1.8	15
35	Editorial. <i>Health Economics (United Kingdom)</i> , 2016, 25, 6-8.	0.8	6
36	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). <i>Open Heart</i> , 2016, 3, e000371.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2016, 172, 160-169.	1.2	93
38	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 19.	0.6	14
39	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 267.	0.7	20
40	BEAT-IT: Comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 595.	0.7	14
41	Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks?. <i>PLoS ONE</i> , 2015, 10, e0119035.	1.1	12
42	Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2015, 18, 161-172.	0.1	539
43	Cost-Effectiveness Uncertainty Analysis Methods. <i>Medical Decision Making</i> , 2015, 35, 596-607.	1.2	14
44	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. <i>European Heart Journal</i> , 2015, 36, 100-111.	1.0	241
45	The “in Cost-Effectiveness Analyses. A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence. <i>Annals of the American Thoracic Society</i> , 2014, 11, S105-S111.	1.5	27
46	Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing Close Contact Casting (CCC) to Open surgical Reduction and Internal Fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 79.	0.8	14
47	Population ageing and healthcare expenditure projections: new evidence from a time to death approach. <i>European Journal of Health Economics</i> , 2014, 15, 885-896.	1.4	38
48	Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. <i>Diabetologia</i> , 2014, 57, 2513-2520.	2.9	30
49	Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. <i>Health Technology Assessment</i> , 2014, 18, v-vi, 1-175.	1.3	68
50	Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. <i>Value in Health</i> , 2013, 16, 703-719.	0.1	237
51	The “Hazards” of Extrapolating Survival Curves. <i>Medical Decision Making</i> , 2013, 33, 369-380.	1.2	36
52	ARE VALUE OF INFORMATION METHODS READY FOR PRIME TIME? AN APPLICATION TO ALTERNATIVE TREATMENT STRATEGIES FOR NSTEMI PATIENTS. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 435-442.	0.2	16
53	Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. <i>PLoS Medicine</i> , 2013, 10, e1001380.	3.9	561
54	How effective is the Forestry Commission Scotland's woodland improvement programme—“Woods In and Around Towns” (WIAT)—at improving psychological well-being in deprived urban communities? A quasi-experimental study. <i>BMJ Open</i> , 2013, 3, e003648.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes. <i>BMJ</i> , The, 2013, 346, e5595-e5595.	3.0	450
56	Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>PLoS ONE</i> , 2013, 8, e72642.	1.1	41
57	SPOILT FOR CHOICE: IMPLICATIONS OF USING ALTERNATIVE METHODS OF COSTING HOSPITAL EPISODE STATISTICS. <i>Health Economics (United Kingdom)</i> , 2012, 21, 1201-1216.	0.8	39
58	Review of statistical methods for analysing healthcare resources and costs. <i>Health Economics (United Kingdom)</i> , 2011, 20, 897-916.	0.8	574
59	Reply to "Evidence is still required for treatment as prevention for riskier routes of HIV transmission". <i>Aids</i> , 2010, 24, 2892-2893.	1.0	1
60	Expanding access to HAART: a cost-effective approach for treating and preventing HIV. <i>Aids</i> , 2010, 24, 1929-1935.	1.0	63
61	Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. <i>Quality of Life Research</i> , 2010, 19, 323-331.	1.5	16
62	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. <i>BMC Medicine</i> , 2010, 8, 23.	2.3	29
63	Access with Evidence Development in the UK. <i>Pharmacoeconomics</i> , 2010, 28, 163-170.	1.7	33
64	Age- and Sex-Specific Trends in Fatal Incidence and Hospitalized Incidence of Stroke in Scotland, 1986 to 2005. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 475-483.	0.9	26
65	Health Economics in Asthma and COPD. , 2009, , 751-760.		0
66	Value based pricing for NHS drugs: an opportunity not to be missed?. <i>BMJ: British Medical Journal</i> , 2008, 336, 251-254.	2.4	178
67	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. <i>Heart</i> , 2007, 93, 1081-1086.	1.2	53
68	Cost-Effectiveness Acceptability Curves in the Dock. <i>Medical Decision Making</i> , 2007, 27, 93-95.	1.2	18
69	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. <i>Journal of Health Services Research and Policy</i> , 2007, 12, 56-58.	0.8	155
70	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. <i>European Heart Journal</i> , 2006, 27, 796-801.	1.0	57
71	Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. <i>Value in Health</i> , 2005, 8, 521-533.	0.1	567
72	Parametric modelling of cost data: some simulation evidence. <i>Health Economics (United Kingdom)</i> , 2005, 14, 421-428.	0.8	84

#	ARTICLE	IF	CITATIONS
73	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics (United Kingdom), 2005, 14, 339-347.	0.8	368
74	Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics, 2005, 23, 529-536.	1.7	49
75	Unfinished Symphony: A Tribute to the Life and Career of Bernie Oâ€™Brien (1959â€“2004). Medical Decision Making, 2004, 24, 538-544.	1.2	1
76	Cost-effectiveness acceptability curvesâ€“ facts, fallacies and frequently asked questions. Health Economics (United Kingdom), 2004, 13, 405-415.	0.8	754
77	The Use of Probabilistic Decision Models in Technology Assessment. Applied Health Economics and Health Policy, 2004, 3, 79-89.	1.0	45
78	Missing.... presumed at random: cost-analysis of incomplete data. Health Economics (United Kingdom), 2003, 12, 377-392.	0.8	280
79	Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. Value in Health, 2002, 5, 312-328.	0.1	26
80	The Design and Analysis of Stochastic Cost-Effectiveness Studies for the Evaluation of Health Care Interventions. Drug Information Journal, 2001, 35, 1455-1468.	0.5	11
81	Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, 7, 723-740.		323
82	An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics, 1998, 13, 397-409.	1.7	713
83	The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation. Journal of Health Services Research and Policy, 1998, 3, 233-245.	0.8	220
84	The Costs and Benefits of Primary Total Hip Replacement:How Likely Are New Prostheses To Be Cost-effective?. International Journal of Technology Assessment in Health Care, 1998, 14, 743-761.	0.2	20
85	Sensitivity analysis in economic evaluation: A review of published studies. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Ove 0.8	0.8	99
86	Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Economics (United Kingdom), 1994, 3, 95-104.	0.8	487
87	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 0, 4, 108.	0.9	15
88	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Research, 0, 4, 108.	0.9	3